Oral anti-cancer pill plus paclitaxel after immunotherapy failure
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and able to sign consent and follow the study plan.
- Your cancer is head and neck squamous cell cancer that cannot be fully removed by surgery and has either returned or spread.
- Your cancer has gotten worse after immune checkpoint therapy (like pembrolizumab or nivolumab).
- You must have at least one measurable cancer spot on scans and a good enough energy level (ECOG 0–2).
- Your blood counts and organ tests (bone marrow, kidneys, liver) must be within allowed limits.
- You must not have had certain prior treatments or conditions (like prior taxane chemotherapy for advanced disease, uncontrolled brain metastases, or specific heart rhythm risks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding medicines given into the tumor (gemcitabine, paclitaxel, and carboplatin) plus nivolumab through a vein can shrink or control head and neck cancer that has come back locally. It’s meant for people whose cancer worsened despite standard treatments like surgery, radiation, and platinum chemotherapy (and cetuximab).
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This study tests whether adding the chemotherapy drug paclitaxel (Taxol) to the targeted therapy cetuximab (Erbitux) is more effective than cetuximab alone for head and neck cancer that has progressed after initial immunotherapy and chemotherapy. Researchers want to see if the combination can help shrink tumors or slow the disease.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.